AI protein specialist Cradle raises US$24m in Series A financing
Generative AI protein engineering specialist Cradle NV, has raised US$24m in a Series A financing round led by Index Ventures w
Repairing MS-caused damage with stem cells
British and Italian researchers have demostrated promising results in patients with progressive multiple sclerosis through stem cell transplantation into the brain.
Breakthrough in COPD treatment
French Sanofi SA’s second Phase III trial of duplimab demonstrated a 34% reduction in exacerbations and significant lung function improvements.
Novo Nordisk invests €2.1bn in production expansion
In the race for global market share of its obesity and diabetes blockbuster semaglutide, Novo Nordisk is expanding production in Europe.<br /><br /><br />
Quotient Therapeutics kicks-off with US$50m financing
Flagship Pioneering has committed US$50m to launch Quotient Therapeutics that links genetic variation at cellular level with disease by Nanoseq, a sequencing method licenced from the Wellcome Sanger Institute.
Solar Foods raises €8m in Series B financing
Finnish protein maker Solar Foods has closed an oversubscribed €8M Series B financing and will expand Solein protein production and support the construction of a commercial production plant.
Germany boosts protein transition with €38m
The Budget Committee of the German Bundestag has announced to channel €38m in funding into the sustainable protein transition next year.<br /><br />
Microharvest GmbH launches SCP-Pilot plant in Lissabon
German precision fermentation specialist MicroHarvest GmbH has launched a single-cell protein pilot plant in Lison with an initial capacity of 25kg per day.
AMR: Partnership set to improve in vivo antibiotics testing
The Innovative Medicine Initiative 2 JU-funded €25m project COMBINE is joining forces with CARB-X & CAIRD, iiCON and Pharmacology Discovery Services to improve in vivo antibiotics testing.
VectorY Therapeutics raises €129m in Series A round
<p itemprop="headline">Dutch VectorY Tx BV has closed one of this yers’s largest Series A financing rounds in Europe at €129m to push its vecorised antibody pipeline in CNS proteinopathies.</p>